SABCS Study Highlights Importance of Ranking Biomarker Evidence in Genomic Test Reports
The study showed that metastatic breast cancer patients are more likely to benefit from precision cancer drugs matched based on biomarkers with strong actionability evidence.
ESR1 Mutation Testing May be Informative for Personalizing SERD Treatment, SABCS Studies Show
Premium
In two studies, testing for ESR1 mutations identified patients who responded particularly well to SERDs.
AstraZeneca, Daiichi Sankyo Unveil First Datopotamab Deruxtecan TNBC Data at SABCS
The companies will conduct a Phase III trial of datopotamab deruxtecan following positive results from a Phase I TNBC cohort presented at the meeting.
PD-L1 Cutoff for TNBC Keytruda Benefit Confirmed in KEYNOTE Analyses, But Questions Linger
Findings confirmed advanced TNBC patients with PD-L1 10 or above benefit from Keytruda, but other data show PD-L1 doesn't predict benefit in earlier-stage TNBC.
Genetic Testing Challenges in Oncology: No Follow-up on Insurer Denial Delays Cancer Risk Management
A case series in partnership with My Gene Counsel to highlight the challenges genetics professionals and oncologists are grappling with as genetic testing is increasingly used in patient care.